Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma.

Total healthcare costs increased with each additional LoT in the R/R DLBCL setting. Further improvements of first-line treatments that reduce the need for subsequent LoTs would potentially lessen the economic burden of DLBCL.